Wednesday, October 19, 2011
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
IN VIVO: The Business & Medicine Report
Pages
Follow Us ...
| ||||||||
Headlines from 'The Pink Sheet' DAILY
Contributors
Labels
About This Blog
Welcome to The IN VIVO Blog, home of daily commentary on recent developments in biopharmaceutical business development, R&D, financing, marketing, and policy. Join us for discussion in the comments, or contact us via email.
Click These Links!
Blog Archive
-
▼
2011
(193)
-
▼
October
(13)
- Deals of the Week Wonders, Will Artemis Help AZ In...
- Financings of the Fortnight Tells A Tale of Two Co...
- So We're Courting Biosimilars After All -- For Mar...
- Deals of the Week Ponders: Is IND the New Biotech ...
- European Regulator-HTA Rapprochement Not Quite There
- Help Name Abbott's Pharma Newco
- IVB Culture Corner: Device Wonkery on the Small an...
- Deals of the Week Considers Another Blockbuster
- Financings of the Fortnight Surveys The Landscape
- The German Biosimilars Breakthrough That Never Was
- Deals Of The Week: PPD/Carlyle Group & Hellman & F...
- No Glass Ceilings: Medtech Women Gather at Unique ...
- Insulin Pricing: Let The Battles Begin
-
▼
October
(13)
Footer
IN VIVO: The Business & Medicine Report
© Copyright 2014 Informa plc.
Informa Business Information. All Rights Reserved.
www.pharmamedtechbi.com
6 comments:
NoJak Pharmaceuticals
AbFab, dahling.
WhiteWash Inc
A-bot Inc
Aboth is best to keep the normal accent while incorporating the humera inital (h) in the name.
and what about BioPharmAbbott?
Post a Comment